Alzinova raises SEK 15.2 million through TO4 warrant exercise
What's the deal? Swedish biotech AlzinovaDealroom has a profile for this one. Try Dealroom → has raised approximately SEK 15.2 million before issuance costs through the exercise of its series TO4 warrants. Around 47.6 million warrants were exercised, representing roughly 94% of all outstanding warrants.
Because the subscription rate hit 94%, a previously announced underwriting commitment will not be needed. The final outcome is expected to be published on June 9.
The signal: Alzinova, still in the early growth stage according to Dealroom, managed to convert 94% of its warrants without tapping underwriting guarantees — a notable feat for a small-cap biotech that remains in the drug discovery phase for Alzheimer's disease. The strong shareholder uptake suggests investors are willing to back early-stage neuroscience plays as the broader Alzheimer's treatment landscape gains momentum following recent approvals of amyloid-targeting therapies.
Read more: MarketScreener
